Opportunities to minimise risk in drug discovery and development

Expert Opinion on Drug Discovery

Volumn 1, Issue 7, 2006, Pages 627-633

  Swinney, David C ^a  

^a Biochemical Pharmacology   (United States)

Author keywords

drug discovery; mechanism; risk; targets

Indexed keywords

EID: 58449131733     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.1.7.627     Document Type: Review

References (29)

1. BLACK J: Personal perspective on Dr Paul Janssen. J. Med. Chem. (2005) 48:1687-1688.
2. NO AUTHORS LISTED: Interview with Sir James Black. Mol. Interv. (2004) 4:139-142.
3. TOBERT JA: Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. (2003) 2:517-526.
4. JACK D: A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other β-adrenoreceptor agonists. Br. J. Clin. Pharmacol. (1991) 31:501-514.
5. SWINNEY DC: Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. Curr. Top. Med. Chem. (2006) 6:461-478.
6. HOPKINS AL, GROOM CR: The druggable genome. Nat. Rev. Drug Disc. (2002) 1:727-730.
7. SWINNEY DC: Biochemical mechanisms of drug action: what does it take for success? Nat. Rev. Drug Discov. (2004) 3:801-808.
8. ARKIN MR, WELLS JA: Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. (2003) 3:301-317.
9. URBAN JD, CLARKE WP, VON ZASTROW M et al.: Functional selectivity and classical concepts of quantitiative pharmacology. J. Pharmacol. Exp. Ther. (2006) Epub ahead of print.
10. MAILMAN RB, GUY EA: Novel mechanism of drug action: functional selectivity at D2 dopamine receptors (a lesson for drug discovery). Med. Chem. Res. (2004) 13:115-126.
11. VAUQUELIN G, VAN LIEFDE I: Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol. Sci. (2006) 27:355-359.
12. FUCHS B, BREITHAUPT-GROGLER K, BELZ GG et al.: Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man. J. Pharm. Pharmacol. (2000) 52:1075-1083.
13. SWINNEY DC: Can binding kinetics translate to a clinically differentiated drug? From theory to practice. Let. Drug Des. Discov. (2006) 3:569-574.
14. RIEDERER P, LACHENMAYER L, LAUX G: Clinical applications of MAO-inhibitors. Curr. Med. Chem. (2004) 11:2003-2043.
15. GRONEMEYER H, GUSTAFSSON J-A, LAUDET V: Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. (2004) 3:950-964.
16. LONG XH, NEPHEW KP: Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α J. Biol. Chem. (2006) 281:9607-9615.
17. LIPTON SA: Paradigm shift in neuroprotenction by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. (2006) 5:160-170.
18. LEE KS, TSEIN RW: Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature (1983) 302:790-794.
19. TIAN G, STUART JD, MOSS ML et al.:17β-(N-tert-butylcarbamoyl)-4-aza- 5 α-androstane-1-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5-α-reductase. Biochemistry (1995) 33:2291-2296.
20. NEMETH EF, HEATON WH, MILLER M et al.: Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther. (2004) 308:627-635.
21. MUFF R, NEMETH EF, HALLER-BREM S, FISCHER JA: Regulation of hormone secretion and cytosolic Ca2+ by extracelluar Ca2+ in parathyroid cells and C-cells: role of voltage-sensitive Ca2+ channels. Arch. Biochem. Biophys. (1988) 265:128-135.
22. JORDAN VC: Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. Clinical considerations and new agents. J. Med. Chem. (2003) 46:1081-1111.
23. WAKELING AF, DUKES M, BOWLER J: A potent specific pure antiestrogen with clinical potential. Cancer Res. (1991) 51:3867-3873.
24. PAUL C, GRAEBER M, STUETZ A: Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin. Investig. Drugs (2000) 9:69-77.
25. ISSA J-P, KANTARJIAN H: Azacitidine. Nat. Rev. Drug Discov. (2005) 4(Suppl.):S6-S7.
26. MATTHEWS T, SALGO M, GREENBERG M, CHUNG J, DEMASI R, BOLOGNESI D: Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. (2004) 3:215-225.
27. OLBE L, CARLSSON E, LINDBERG P: A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat. Rev. Drug Discov. (2003) 2:132-225.
28. LITTMAN BH, WILLIAMS SA: The ultimate model organism: progress in experimental medicine. Nat. Rev. Drug Discov. (2005) 4:631-647.
29. SMITH DA, SCHMID EF: Drug withdrawals and the lessons within. Curr. Opin. Drug Discov. Dev. (2006) 9:38-46.